Q4 Earnings Estimate for MNMD Issued By Leerink Partnrs

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Research analysts at Leerink Partnrs decreased their Q4 2024 earnings estimates for Mind Medicine (MindMed) in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of ($0.31). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.60) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($1.20) EPS.

Several other brokerages have also recently issued reports on MNMD. Evercore ISI initiated coverage on shares of Mind Medicine (MindMed) in a report on Tuesday. They set an “outperform” rating and a $23.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Mind Medicine (MindMed) in a report on Friday. Chardan Capital initiated coverage on Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a “buy” rating and a $20.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. Finally, Leerink Partners initiated coverage on Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Mind Medicine (MindMed) presently has a consensus rating of “Buy” and an average target price of $26.33.

Mind Medicine (MindMed) Stock Performance

Shares of MNMD stock opened at $6.79 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The business has a fifty day moving average of $7.26 and a 200 day moving average of $6.93. The firm has a market capitalization of $497.92 million, a price-to-earnings ratio of -3.00 and a beta of 2.60. Mind Medicine has a 1 year low of $3.82 and a 1 year high of $12.22.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. During the same quarter in the previous year, the business earned ($0.53) earnings per share.

Insider Activity at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 19,106 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $141,957.58. Following the sale, the chief executive officer now directly owns 526,666 shares in the company, valued at approximately $3,913,128.38. The trade was a 3.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dan Karlin sold 6,643 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares in the company, valued at $2,511,436.59. The trade was a 1.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,022 shares of company stock valued at $208,203. 2.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in Mind Medicine (MindMed) by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,677,702 shares of the company’s stock valued at $9,548,000 after purchasing an additional 162,933 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Mind Medicine (MindMed) by 142.6% during the third quarter. Wellington Management Group LLP now owns 185,722 shares of the company’s stock worth $1,057,000 after buying an additional 109,152 shares during the period. Barclays PLC grew its stake in shares of Mind Medicine (MindMed) by 203.6% in the third quarter. Barclays PLC now owns 136,098 shares of the company’s stock valued at $775,000 after buying an additional 91,271 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Mind Medicine (MindMed) in the 3rd quarter valued at $337,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Mind Medicine (MindMed) during the 3rd quarter worth about $298,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.